For the first time, the U.S. Food and Drug Administration (FDA) has approved the use of a ketamine-like drug as a stand-alone therapy for adults with treatment-resistant depression (TRD).

Tesla and SpaceX CEO Elon Musk clarified that he uses only "a small amount once every other week or something like that" ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

The 2019 winner of "RuPaul's Drag Race UK," who died in January, had experienced cardiac arrest following ketamine use, The ...

The inferior molecule of ketamine — SPRAVTO or esketamine, which Johnoson & Johnson patents — has been FDA-approved for TRD. SPRAVTO is a nasal spray administered to patients. Still, it does not have ...

Limitless provides immersive guided visualizations that help patients feel safe and anchored while leveraging the neuroplasticity created by ketamine. For patients undergoing Spravato (esketamine ...

This is because the Food and Drug Administration (FDA) only approves the drug ketamine for use in general anesthetics. However, Medicare may cover the drug Spravato, which contains esketamine.

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

In 2019, the FDA approved a nasal spray containing a form of ketamine called esketamine (sold under the brand name Spravato) for patients with depression who hadn’t responded to other treatments.

"With Limitless Guided Visualizations, we're able to offer our patients an added layer of support that complements their ...